Table 2 Description of both populations
Training data set ( n =2110) | Validation data set ( n =306) | ||
|---|---|---|---|
Parameters | n , % (95 CI) | n , % (95 CI) | P -value ( χ 2 -test) |
Early death | 0.003 | ||
Yes | 344, 16.3% (14.7–17.8) | 30, 9.8% (6.4–13.1) | |
Missing data | 0 | 0 | |
Gender | <0.001 | ||
Women | 1194, 56.6% (54.5–58.7) | 135, 44.1% (38.5–49.7) | |
Missing data | 0 | 0 | |
Primaries | <0.001 | ||
Colorectal cancers | 367/17.4% (15.7–19.0) | 87/28.4% (23.3–33.4) | |
Oesophago-gastric cancers | 275/13.0% (11.6–14.4) | 15/4.9% (2.5–7.3) | |
Gynaecological cancers | 249/11.8% (10.4–13.2) | 18/5.9% (3.2–8.5) | |
Sarcomas | 216/10.2% (8.9–11.5) | 15/4.9% (2.5–7.3) | |
Lung cancers | 214/10.1% (8.8–11.4) | 10/3.3% (1.3–5.3) | |
Melanoma | 157/7.4% (6.3–8.5) | 21/6.9% (4.1–9.7) | |
Prostate cancer | 148/7.0% (5.9–8.1) | 1/0.3% (0–0.9) | |
Breast cancers | 142/6.7% (5.6–7.8) | 40/13.1% (9.3–16.9) | |
Other genitourinary cancers | 108/5.1% (4.2–6.0) | 17/5.6% (3.0–8.2) | |
Head and neck | 94/4.5% (3.6–5.4) | 71/23.2% (18.5–27.9) | |
Others | 140/6.6% (5.5–7.6) | 11 (3.6%) | |
Missing data | 0 | ||
ECOG-PS | <0.001 | ||
0 | 857/40.6% (38.4–42.8) | 155/50.7% (45.1–56.3) | |
1 | 1186/56.2% (54.1–58.4) | 140/45.8% (40.2–51.4) | |
2 | 67/3.2% (2.4–3.9) | 11/3.6% (1.5–5.7) | |
Missing data | 0 | 0 | |
First-in-man | |||
Yes | 930/44.1% (42.0–46.1) | 0/0% (−) | |
Missing data | 0 | ||
Investigational treatments | <0.001 | ||
Targeted agent (single-agent) | 940/44.5% (42.4–46.6) | ||
Cytotoxic agents | 460/21.8% (19.3–24.3) | 306/100% (−) | |
Targeted+cytotoxic agents | 543/25.7% (23.8–27.6) | ||
Combination of targeted agents | 167/7.9% (6.7–9.0) | ||
Missing data | 0 | ||
